Myriad Genetics, Inc. ( MYGN Quick Quote MYGN - Free Report) recently announced its entry into a strategic collaboration with Illumina, Inc. ( ILMN Quick Quote ILMN - Free Report) for improved outcomes in oncology. Per the terms of the time-limited exclusive agreement, Illumina will create a kit-based version of Myriad Genetics’ myChoice companion diagnostic (CDx) test for the international market.
Per Myriad Genetics’ management, this recently announced agreement between the two companies will enable the combination of companion diagnostics with next-generation sequencing. This combination can be utilized to advance comprehensive genomic profiling of tumor samples and derive better outcomes in oncology.
For investors’ note, myChoice CDx test is CE Marked, which has also received the Japanese regulatory approval for use as a companion diagnostic with Lynparza (olaparib) for first-line maintenance treatment in ovarian cancer in conjunction with bevacizumab. Lynparza is a PARP inhibitor jointly developed and commercialized by AstraZeneca and Merck.
Myriad Genetics’ recent partnership with Illumina is expected to provide a significant boost to its Molecular Diagnostic Testing business on a global scale.
Rationale Behind the Partnership
The collaboration will help Myriad Genetics to expand the access as well as extend the reach of myChoice CDx through its services offering. On the other hand, the partnership will allow Illumina to leverage its sequencing instrument install base and knowledge from growing market adoption of its TruSight Oncology 500 next-generation sequencing assay. This, in turn, will enable it to develop and commercialize the globally distributed kits for the assessment of homologous recombination deficiency (“HRD”) along with other proprietary biomarkers.
Illumina’s management believes that the rising adoption of PARP inhibitor therapeutics for the broader HRD patient population is crucial for the partnership. This belief stems from Illumina’s anticipation that the future of healthcare will depend on molecular-based testing for better patient outcomes through standardized and better testing with myChoice CDx.
Industry Prospects Per a report by Grand View Research, the global molecular diagnostics market size was valued at $9.2 billion in 2019 and is anticipated to reach $18.2 billion by 2027 at a CAGR of 9%. Factors like technological advancements in molecular diagnostics and growing prevalence of infectious diseases are expected to boost the market.
Given the market potential, the partnership seems to have been timed well.
Recent Developments in Molecular Diagnostics
Of late, Myriad Genetics has been witnessing a slew of developments in its business.
The company, this month, announced the receipt of its first reimbursement decision for the myChoice Diagnostic System, which helps determine whether women with ovarian cancer will benefit from the PARP inhibitor Zejula (niraparib). Notably, myChoice was approved by Japan’s Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication, whose reimbursement decision is now in effect.
Myriad Genetics had announced the expansion of its myChoice tumor testing in various European markets and China in November 2020. The same month, the company presented new data which demonstrated that Vectra testing and three additional biomarkers, combined with traditional risk factors, can predict the risk of cardiovascular events in patients with rheumatoid arthritis. The company also presented a study which showed that Vectra is a significant predictor for joint damage and is a better predictor than several tested subjective measures.
In October 2020, Myriad Genetics announced the successful completion of the method evaluation assessment for the EndoPredict breast cancer prognostic test by the German Federal Joint Committee.
Shares of the company have lost 9.6% in the past year against the
industry’s 9.2% growth and the S&P 500’s 18.3% rise. Zacks Rank & Key Picks
Currently, Myriad Genetics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are
Hologic, Inc. ( HOLX Quick Quote HOLX - Free Report) and IDEXX Laboratories, Inc. ( IDXX Quick Quote IDXX - Free Report) .
Hologic’s long-term earnings growth rate is estimated at 17.4%. The company presently carries a Zacks Rank #1 (Strong Buy). You can see
the complete list of today’s Zacks #1 Rank stocks here.
IDEXX’s long-term earnings growth rate is estimated at 15.8%. It currently carries a Zacks Rank #2 (Buy).
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by referendums and legislation, this industry is expected to blast from an already robust $17.7 billion in 2019 to a staggering $73.6 billion by 2027. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot stocks we're targeting >>